Enamine Announces Extension of Collaboration with Sanofi in Early Drug Discovery
News Dec 19, 2014
Enamine Ltd has announced that it has extended its collaboration agreement with Sanofi, an integrated global healthcare leader. Based on the success of the collaboration to date, the extension enables Sanofi to continue to access Enamine’s in-house designed and synthesized screening compound library, and select a library subset of novel drug-like screening compounds, according to Sanofi’s research needs.
Enamine’s library, which is now the industry’s most extensive range with 2,000,000 compounds, provides Sanofi with an optimal starting point for hit finding activities for multiple therapeutic targets and will be used at Sanofi’s worldwide screening facilities.
Michael Bossert, Head of Strategic Alliances at Enamine, commented: “We have worked with Sanofi since 2012 and are delighted to continue our agreement. At Enamine our focus is on the development of original and unique chemistry, and this extension reflects our scientific knowledge and ability to exceed partner expectations. The collaboration involves regular communication with Sanofi teams and is focused on facilitating the creation of new research projects to support the emergence of effective treatments for diseases.”
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Antimicrobial Found in Toiletries Could be Used Against MalariaNews
Triclosan, an antimicrobial compound used in soap, toothpaste, deodorant and many other products, can inhibit target genes in the malaria parasite during two crucial stages of its lifecycle in humans - the hepatic stage.READ MORE
Pre-Treatment with Targeted Drugs Could Mean Less Breast Cancer Patients Require Radical SurgeryNews
Extensive surgery involving mastectomy and removal of several lymph nodes can be safely avoided for more women with some types of breast cancer, if they receive targeted drugs before surgery, according to research presented at the 11th European Breast Cancer Conference.READ MORE